Cyclobenzaprine Hydrochloride Tablets recalled over manufacturing violations
- Recall date
- July 29, 2021
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Teva Pharmaceuticals USA recalls Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laborator…
- Recall number
- D-0776-2021
- FDA classification
- Class II
- Brand / firm
- Teva Pharmaceuticals USA
- Sold / distributed
- Product was distributed nationwide.
Why it was recalled
CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 57237-266-01
Get recall alerts
Free email alert whenever Teva Pharmaceuticals USA has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Teva Pharmaceuticals USA